Cerebral Folate Deficiency: When Your Brain Isn't Getting the Folate It Needs
Understanding the science behind folate receptor autoantibodies, why conventional testing often misses them, and how targeted treatment can change lives.
A child isn't meeting developmental milestones. Speech has stalled. Behaviors have changed. Seizures have appeared. They struggle with attention, movement, learning, or sleep. The parent is suspecting ADHD, OCD, or even Autism Spectrum.
The list of symptoms is pretty extensive to date, as they are finding the effects of folate deficiency because folate acts on so many areas of the body. In addition to what is already mentioned. Research for children is being conducted in other conditions, but one of the biggest underlying themes is developmental regression. Parents often describe a child who was making progress, acquiring words, learning new skills, or interacting socially, only to gradually lose those abilities.
Regression can involve loss of language, reduced eye contact, loss of social engagement, decline in motor coordination, new repetitive behaviors, increased irritability, new seizures, and cognitive slowing. Regression should always prompt a thorough medical evaluation because it suggests that something has changed within the nervous system. Please note that cerebral folate deficiency is only one of many potentially treatable causes to consider.
For an adult, they may experience:
Cognitive symptoms such as brain fog, poor concentration, poor short-term memory, struggles with executive function, mental fatigue, or poor word recall
Neurological symptoms such as chronic fatigue, tremor, migraines resistant to treatment, poor balance, or dizziness
Mental health symptoms such as generalized anxiety, panic disorder, OCD, mood instability, emotional dysregulation, sleep disturbances associated with neurological symptoms or depression.
Many have a medical history that is hard to make sense of, like POTS, MCAS, or multiple chemical sensitivities, or complex conditions such as autoimmune disorders like Rheumatoid arthritis, Lupus, Psoriasis
Full workup- blood work looks normal. Brain imaging may be normal. Vitamin levels appear "fine." Yet something clearly isn't right.
"Everything came back normal."
For many families and adults, those words become painfully familiar.
Over the last decade, researchers have uncovered one possible explanation that was almost completely unknown just twenty years ago: Cerebral Folate Deficiency (CFD).
Although still unfamiliar to many healthcare providers, cerebral folate deficiency has become one of the more interesting areas of neurological research because, unlike many neurological disorders, it may be identifiable through specialized testing and, in some cases, treatable.
Even more remarkable is that many people with cerebral folate deficiency have completely normal blood folate levels.
How can someone have enough folate in their bloodstream but not enough reaching their brain? The answer lies in a tiny protein called the folate receptor alpha, one of the brain's most important transport systems. Understanding how this system works opens an entirely different way of thinking about neurological disease.
Please keep in mind that these symptoms do not diagnose cerebral folate deficiency, nor are they unique to the condition. However, when they occur without another clear explanation, particularly in the setting of autoimmune disease, autism spectrum disorder, epilepsy, or mitochondrial dysfunction, they may justify further evaluation with specialized testing for folate receptor alpha autoantibodies.
What Is Cerebral Folate Deficiency?
Cerebral folate deficiency (CFD) is a neurological condition in which the brain does not receive enough biologically active folate despite adequate, and often completely normal, folate levels in the bloodstream. This is an important distinction. Most people think of folate deficiency as something caused by poor diet or inadequate vitamin intake. In those situations, blood folate levels are low because the body simply does not have enough folate available. Cerebral folate deficiency is different.
In many individuals with CFD, the body has plenty of folate circulating through the bloodstream. The problem is that the folate cannot efficiently cross the blood-brain barrier and enter the central nervous system, where it is needed to support normal brain development, repair, neurotransmitter production, and countless other neurological functions. Imagine ordering supplies for a construction project. The delivery truck arrives at the front gate carrying everything the workers need, but the gate never opens. The supplies are present; they simply never reach their destination. That is essentially what happens in many cases of cerebral folate deficiency.
Why Does the Brain Need Folate?
Folate is far more than just a vitamin involved in preventing anemia or supporting pregnancy. Inside the brain, folate participates in dozens of essential biochemical pathways. Without adequate folate, the brain struggles to perform many of its most fundamental tasks, including:
Producing and repairing DNA
Supporting normal brain development
Forming healthy myelin around nerves
Producing neurotransmitters such as dopamine, serotonin, and norepinephrine
Supporting methylation reactions
Repairing neurons after injury
Protecting against oxidative stress
Maintaining normal communication between brain cells
Supporting learning, memory, and cognitive function
Because folate is involved in so many neurological processes, cerebral folate deficiency can present in many different ways. There is no single "classic" symptom. Instead, patients often develop a constellation of neurological, developmental, psychiatric, and behavioral concerns that can initially appear unrelated.
Why Is Cerebral Folate Deficiency Frequently Missed?
One of the biggest reasons cerebral folate deficiency remains underdiagnosed is that most routine laboratory testing cannot detect it. When patients complain of neurological symptoms, providers commonly order:
Complete blood count (CBC)
Vitamin B12
Serum folate
Red blood cell folate
Comprehensive metabolic panel
Thyroid testing
If these tests return within normal limits, folate deficiency is often dismissed as a possibility. Unfortunately, normal blood folate does not tell us whether adequate folate is actually reaching the brain. This distinction is absolutely critical. Blood tests measure what is circulating through your bloodstream. They do not measure what has successfully crossed the blood-brain barrier into the cerebrospinal fluid, where the brain depends on folate to function properly. For this reason, many individuals with cerebral folate deficiency have perfectly normal serum folate concentrations. They are not deficient in folate. They are deficient in brain folate.
The Science Behind Cerebral Folate Deficiency
Your Brain Has Its Own Security System
If you were to inject dye into your bloodstream, you might assume it would eventually travel throughout your entire body, including your brain. Surprisingly, that's not what happens. Your brain is protected by one of the most remarkable defense systems in the human body, known as the blood-brain barrier (BBB). Rather than acting like a simple filter, the BBB is an incredibly selective border made up of tightly connected cells lining the brain's blood vessels. Its primary job is to protect the central nervous system from bacteria, viruses, toxins, inflammatory molecules, and other potentially harmful substances circulating throughout the bloodstream. This barrier is one reason our brains remain protected despite being exposed to countless environmental substances every day.
The downside is that the blood-brain barrier doesn't just keep harmful substances out. It also makes it much harder for beneficial nutrients to get in. Nutrients such as glucose, amino acids, iron, and folate all require specialized transport systems to cross from the bloodstream into the cerebrospinal fluid (CSF), the fluid that bathes and nourishes the brain and spinal cord. In other words, the brain cannot simply absorb folate because it is present in the bloodstream. It must be actively transported across the blood-brain barrier. This distinction is the foundation of cerebral folate deficiency.
Folate Must Earn Its Way Into the Brain
Folate (vitamin B9) is essential for every cell in the body, but it is particularly critical within the developing and functioning nervous system. Unlike many tissues throughout the body, the brain depends heavily on a specialized transport protein called folate receptor alpha (FRα). This receptor is highly concentrated within the choroid plexus, the structure responsible for producing cerebrospinal fluid. Its job is to recognize circulating folate, bind to it with remarkable precision, transport it across the blood-brain barrier, and release it into the cerebrospinal fluid where it becomes available to neurons and other brain cells. Think of folate receptor alpha as a highly trained customs officer stationed at the entrance to the brain.
Every folate molecule approaching the blood-brain barrier must be recognized, escorted through the checkpoint, and safely delivered into the central nervous system before it can participate in normal neurological function. When this transport system works properly, the brain maintains folate concentrations that are actually higher than those found in the bloodstream, ensuring a continuous supply for the enormous metabolic demands of the nervous system. When transport is impaired, however, the brain gradually becomes deprived of folate despite normal circulating levels elsewhere in the body. This is why cerebral folate deficiency is better thought of as a transport disorder rather than a nutritional deficiency.
When the Immune System Gets in the Way
For many years, researchers understood that some children had unusually low folate concentrations in their cerebrospinal fluid despite having completely normal folate levels in their blood. What remained a mystery was why the transport system had failed. That mystery began to unravel through the work of Dr. Edward Quadros, who discovered that some individuals produce folate receptor alpha autoantibodies. These antibodies mistakenly target the very receptor responsible for transporting folate into the brain. Instead of attacking bacteria or viruses, the immune system begins interfering with one of the body's own nutrient transport systems. This represents a form of autoimmune dysfunction rather than a dietary deficiency.
Over the past two decades, Dr. Richard Frye and colleagues have expanded this work considerably, demonstrating that these autoantibodies are found in a substantial subset of children with autism spectrum disorder and are also associated with cerebral folate deficiency and several other neurodevelopmental and neuropsychiatric conditions. Their work has helped shift the conversation from simply asking whether someone has enough folate to asking whether that folate is actually reaching the brain.
This is one of the most important conceptual shifts in understanding cerebral folate deficiency.
The question is no longer:
"Do you have enough folate?"
Instead, we ask:
"Can your brain actually access the folate you already have?"
Where is the Research and Evidence, and where is Current Research?
We are still learning a lot day to day, and nothing is set in stone yet regarding evidence and treatment; this is why most general practitioners and pediatricians are not aware of it or are not sure how to treat.
Cerebral folate deficiency is still a relatively young area of medicine. One reason many physicians have never heard of folate receptor alpha autoantibodies is that much of what we know today has emerged over approximately the last two decades. A relatively small group of researchers has been responsible for much of the foundational and clinical work.
Dr. Edward Quadros: Understanding the Folate Receptor and Autoantibodies
Edward V. Quadros, PhD, at SUNY Downstate Medical Center, is one of the foundational researchers in this field. His research has helped characterize folate receptor alpha (FRα), the autoantibodies directed against this receptor, and how these antibodies may interfere with folate transport.
Some of the earliest evidence came from research demonstrating folate receptor autoantibodies in women with pregnancies complicated by neural tube defects. Soon afterward, Quadros, Dr. Vincent Ramaekers, and colleagues demonstrated something particularly important: children could have low cerebrospinal fluid 5-methyltetrahydrofolate (5-MTHF) levels while maintaining normal serum and red blood cell folate levels. In their landmark 2005 study of 28 children with infantile-onset cerebral folate deficiency, 25 had high-affinity blocking autoantibodies against the folate receptor. 2005 New England Journal of Medicine CFD study on PubMed
Quadros and colleagues have continued investigating folate receptor autoantibodies, including the development and clinical utility of blood testing, their presence in autism and family members, and their potential significance during pregnancy.
Folate receptor autoantibodies in children with autism, siblings and parents
Diagnostic utility of folate receptor autoantibodies in blood
Dr. Vincent Ramaekers: Defining Cerebral Folate Deficiency as a Neurological Syndrome
Vincent T. Ramaekers, MD, a pediatric neurologist, is another major name readers will repeatedly encounter in the CFD literature. His early work helped characterize cerebral folate deficiency as a neurological syndrome and demonstrated the connection between low CSF folate, folate receptor autoantibodies, and neurological dysfunction.
Ramaekers has collaborated extensively with Quadros. Their research helped establish the autoimmune mechanism through which folate receptor autoantibodies can interfere with folate transport into the central nervous system. They have also investigated the relationship between folate receptor autoimmunity and milk consumption. A 2008 clinical study found that a milk-free diet was associated with lower folate receptor autoantibody concentrations, while re-exposure to cow's milk was associated with increasing antibody titers. This remains an interesting and evolving area of research. Ramaekers and Quadros study on folate receptor autoimmunity and a milk-free diet
Dr. Richard Frye: Connecting CFD, Autism, Mitochondrial Function and Folinic Acid Treatment
Richard E. Frye, MD, PhD, is one of the most prominent clinical researchers currently studying cerebral folate deficiency, folate receptor alpha autoantibodies, autism spectrum disorder, mitochondrial dysfunction, and the treatment with high-dose folinic acid, also known as leucovorin.
Dr. Frye's research is particularly important because it moves the discussion beyond identifying an antibody and asks the much more clinically relevant question: If folate transport is impaired, can bypassing that problem improve neurological function?
A 2021 systematic review and meta-analysis by Dr. Frye and Dr. Daniel Rossignol brought together much of the available research on CFD, folate receptor alpha autoantibodies, autism, and leucovorin treatment. Their analysis found a pooled FRAA prevalence of approximately 71% among individuals with autism across the included studies. Importantly, a positive antibody does not mean that 71% of children with autism have clinically established cerebral folate deficiency. Frye and Rossignol systematic review and meta-analysis
More recent work is becoming even more interesting. In 2024, Frye and colleagues reported that the binding folate receptor alpha autoantibody may help identify children with autism who are more likely to respond to leucovorin treatment. This is important because it begins moving FRAA testing toward something more clinically useful than simply determining whether an antibody is present. It raises the possibility that the type and concentration of antibody could eventually help clinicians predict treatment response. 2024 study on binding FRAA as a biomarker of leucovorin response
Dr. Frye's group is also expanding this research beyond classic autism and developmental disorders. A 2024 study examined FRAAs in children with PANS/PANDAS, while a newly published 2026 study investigated folate receptor alpha autoantibodies in patients with vector-borne diseases. These studies do not establish FRAAs as a cause of PANS, PANDAS, Lyme disease, or other vector-borne illness, but they demonstrate how researchers are beginning to ask whether impaired folate transport and folate receptor autoimmunity may occur across a broader range of inflammatory and neurological conditions. 2024 FRAA research in PANS/PANDAS, 2026 FRAA research in vector-borne disease populations
Even more recently, Frye, Quadros, and colleagues published research in 2025 examining transgenerational effects and the potential heritability of folate receptor alpha autoantibodies in families affected by autism. This builds upon earlier observations that FRAAs can also be detected in siblings and parents, suggesting that the biology may extend well beyond the individual child being evaluated. 2025 study on transgenerational effects and heritability of FRAAs
How do we test for CFD?
At present, the only company performing autoantibody testing is Religen called FRAT®. FRAT® stands for Folate Receptor Autoantibody Test. It is a specialized blood test developed from research by Dr. Edward Quadros that detects autoantibodies directed against folate receptor alpha (FRα).
FRAT® measures both blocking autoantibodies, which directly interfere with folate binding to the receptor, and binding autoantibodies, which bind to the receptor and may impair its normal function. A positive result supports the presence of folate receptor autoimmunity and possible impaired folate transport, but the test does not directly measure the amount of folate within the brain or CSF.
FRAT® requires a blood draw and an order from a medical professional. The blood sample is collected locally and shipped to the laboratory according to the kit instructions, and results are returned to the ordering provider.
Two Different Types of Autoantibodies
One reason FRAT® testing is unique is that it evaluates two distinct categories of folate receptor alpha autoantibodies: blocking and binding.
Although both interfere with folate transport, they appear to do so in slightly different ways.
Blocking Autoantibodies
Blocking autoantibodies do exactly what their name suggests.
They physically block folate from attaching to the folate receptor alpha. Imagine placing a piece of chewing gum into a lock. Even if you have the correct key, it can no longer enter the lock because something else is occupying that space.
When blocking antibodies occupy the receptor, folate simply cannot bind efficiently, resulting in reduced transport into the cerebrospinal fluid. This represents the more direct mechanism of transport disruption.
Binding Autoantibodies
Binding autoantibodies are a little more complex.
Rather than blocking the exact location where folate attaches, they bind elsewhere on the receptor. Current evidence suggests that this alters the receptor's normal orientation or function, thereby making folate transport less efficient even though the receptor itself remains present. Researchers continue to study this mechanism, but the end result appears to be similar: less folate reaches the brain.
Importantly, some individuals produce only blocking antibodies, others only binding antibodies, and others both. This is precisely why modern FRAT® testing measures both types rather than only one. Testing only for blocking antibodies would miss an entire group of patients whose folate transport may still be impaired via binding.
What do I do if I suspect my child or I have CFD?
Get tested by contacting me! I frequently order and interpret these test results.
If you want to discuss it with your current medical provider, call the office or your provider first to ask whether they are familiar with CFD and the test before scheduling an appointment. If they do not know anything about it, reach out to me, and I can help you find someone who does. This area of medicine continues to evolve; some medical professionals are not yet knowledgeable about it.
Here to empower you with the knowledge of health,
Dr. Meg Holpuch
Disclaimer: The information provided on this blog is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The content shared here is not meant to replace or supersede the guidance or recommendations of your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your diet, exercise routine, supplement regimen, or overall health plan. Your health and well-being are unique, and decisions regarding your care should always be made in consultation with your trusted healthcare provider.
